NeoGenomics arrives at tonight's earnings release with short sellers meaningfully more active than they were just weeks ago — and options hedging still running well above its recent baseline.
Short interest has accelerated sharply since the prior earnings preview. At 10.3% of the free float, the short position has grown 16% over the past week and 47% over the past month — a notable step-up from the 8.9% level flagged in the July 25 article. That build is worth watching, but the lending market is not yet signalling distress. Borrow availability is loose at 343% of outstanding short interest, comfortably within normal territory, and the cost to borrow sits at a benign 0.52%. Bears have added to their positions, but they are doing so with room to spare and at minimal carrying cost.
Options positioning has remained elevated through the run-up to the print. The put/call ratio hit 0.052 on Tuesday, more than two standard deviations above its 20-day average of 0.017 — consistent with the defensive tilt identified ahead of the July 28 date. The stock gave back another 7% on the week to close at $13.40, paring the month's losses to roughly 5%. Correlated peers have also weakened: PRVA dropped 6% on the week, and fell nearly 8%, suggesting broader sector pressure rather than NEO-specific selling.
The bull and bear divide is clearest on the revenue mix. Bulls point to gross margin expansion — 150 basis points to 46.8% — and NGS testing revenue growth of 18% in Q1, alongside an EPS momentum score ranking in the 94th percentile on a 90-day basis. Benchmark raised its price target to $16 just last week, maintaining its Buy rating, and the consensus mean target implies roughly 25% upside from current levels. Bears counter with non-clinical sales that missed consensus by nearly 15%, ongoing reimbursement risk, and a PE multiple near 45x on a stock that remains loss-making on reported figures. The ORTEX short score of 60.2 is elevated but stable, suggesting the market is pricing in genuine uncertainty rather than one-directional conviction.
The print tonight tests whether the margin story has legs — specifically whether the operating improvements that drove analyst upgrades earlier this year are durable enough to absorb the revenue-mix headwinds that have kept short sellers engaged.
See the live data behind this article on ORTEX.
Open NEO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
